Chronic Lymphocytic Leukemia Cells May Become Less Dependent on Nurse-Like Cells during Later Stages of Disease.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4805-4805
Author(s):  
Tomoyuki Endo ◽  
Mitsufumi Nishio ◽  
Laura Rassenti ◽  
Arnon P. Kater ◽  
Thomas J. Kipps

Abstract A subset of blood mononuclear cells from patients with B-cell chronic lymphocytic leukemia (CLL) can differentiate into large, adherent cells, termed “nurse-like cells” (NLC), that can attract CLL cells and protect them from undergoing apoptosis in vitro. When removed from NLC in vitro, CLL cells often undergo spontaneous apoptosis. We observed that the relative viability of isolated CLL cells cultured without versus with NLC appeared constant for any one sample in different experiments and did not vary with the source of the NLC used in any one experiment. Furthermore, the isolated CLL cells from some patients could survive in vitro without NLC better than could the leukemia cells of other patients. We examined for characteristics associated with CLL cells that were more or less reliant on NLC for survival in vitro. For this, we defined CLL cell populations as having “low dependency” on NLC when the relative leukemia cell viability after two days culture without NLC was less than one half-log (33%) lower than that of the same CLL cells co-cultured with NLC. Using a Multiplex Ligation-dependent Probe Amplification (MLPA) assay, we examined CLL cell populations with low dependency (n = 4) versus samples with high dependency (n = 5) for expression of 40 distinct mRNA that encoded known pro-apoptotic or anti-apoptotic proteins. CLL cells with low dependency expressed significantly higher levels of BCL-2, and significantly lower levels of BAX-2 than CLL cells with high NLC dependency. There was no significant difference between the mean white blood cell counts of patients whose CLL cells had low-dependency versus those whose cells had high dependency on NLC in vitro. However, in the high dependency group there was a significantly higher proportion of cases that expressed ZAP-70 than in the group with low dependency. This association, however, could reflect the fact that many of the samples with low dependency were acquired from patients who had long-established disease, a characteristic that typically was not associated with patients who have CLL cells that expressed ZAP-70. The mean time from diagnosis to the date of sample collection was significantly longer (m = 66.6 ± 47.0 months, median = 49 months, n=30) for samples with low dependency than it was for those cases with high dependency (m = 41.2 ± 25.1 months, median = 39.5 months, n=20) (p=0.017). Furthermore, evaluation of serial samples collected over years from the same patients (n = 5) revealed that the relative dependency of CLL cells on NLC could decrease significantly over time. In none of the serial samples did we observe increased dependency of the CLL cells on NLC over time or over that observed for the CLL cells isolated from the initial sample collection. These data suggest that over the course of the disease CLL cells might acquire less dependency on NLC, and potentially also on its stromal microenvironment.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3116-3116 ◽  
Author(s):  
Danelle F. James ◽  
Maryann R. Betty ◽  
Ruzbeh Mosadeghi ◽  
Thomas J. Kipps

Abstract Lenalidomide (3-(4-amino-1-oxo-3H-isoindol-2-yl)piperidine-2,6-dione)) is an agent approved for treatment of patients with del 5q myelodysplastic syndromes and previously treated multiple myeloma. Lenalidomide has been found in early clinical trials to have potential therapeutic activity in patients with relapsed chronic lymphocytic leukemia (CLL). The mechanism(s) whereby this drug is active in CLL is unknown. In particular, studies to date have not found lenalidomide to have any direct cytotoxic activity on CLL cells in vitro. This has stimulated speculation that this agent might adversely affect the positive influence of the microenvironment on leukemia-cell survival. We and others have observed that cells found in the leukemia microenvironment can support CLL-cell survival in vitro. One such type of cells are nurse-like cells (NLC), which can differentiate from the CD14-positive blood mononuclear cells of CLL patients into large, round adherent cells that can attract and support CLL cell survival in vitro for weeks, if not longer. We evaluated the effects of lenalidomide on primary leukemia-cell survival in vitro when the CLL cells from different patients (N=21) were cultured alone or together with NLC generated as previously described [Tsukada Blood 2002]. We assessed the in-vitro activity of lenalidomide on primary CLL cells from 21 patients, in duplicate in a series of 6 experiments. Lenalidomide at concentrations of 0.1μM-200μM did not significantly impact the survival of CLL cells that were cultured alone for up to 12 days. Analysis of cell surface markers revealed increased expression of CD38 at 36 hours in 5/5 lenalidomide treated CLL samples compared with untreated cells (MFIR 5.7 +/− .86 vs. 3.4 +/− .83 p=.003). We observed sustained upregualtion of CD40 and regulation of CXCR4 in the majority of cells treated with lenalidomide. When cultured with NLC, the survival of CLL cells was comparable to or significantly higher than that of CLL cells cultured alone 62.4% vs. 51% (+/−3% SEM n=21 p [<] 0.0005). The addition of lenalidomide at concentrations of 0.1μM and greater to co-cultures of NLC and CLL cells caused specific reductions in CLL cell survival to levels similar to or lower than that of CLL cells cultured without NLC. In the presence of NLC, lenalidomide at 1μM reduced CLL cell viability compared to control (41.5% vs. 56% +/−4% p [<] 0.0005 paired student t test n=13). For most patients the levels of CLL cell viability on days 4 through 8 in the co-cultures with lenalidomide was significantly lower than those of CLL cells co-cultured with NLC in the absence of lenalidomide. As such, this study reveals that physiologic concentrations of lenalidomide might abrogate the protective influence of NLC on CLL cell survival in vitro and potentially in vivo. Conceivably, those patients who have leukemia cells displaying a high dependency on NLC for survival in vitro also might be most likely to experience a favorable clinical response to treatment with lenalidomide. This hypothesis will be tested in a prospective manner with a planned clinical trial evaluating lenalidomide for treatment of CLL through the CLL Research Consortium.


Blood ◽  
1994 ◽  
Vol 84 (7) ◽  
pp. 2297-2304 ◽  
Author(s):  
T Mainou-Fowler ◽  
VA Craig ◽  
JA Copplestone ◽  
MD Hamon ◽  
AG Prentice

Abstract During hematopoiesis, viability factors that suppress apoptosis are required throughout the differentiation process. Some of these factors may also function as growth factors. Interleukin-5 (IL-5) is recognized as a growth factor in hematopoiesis. We examined the involvement of IL- 5 as a viability factor of B-CLL in vitro. In 13 B-CLL cases studied, IL-5 at 20 U/mL increased spontaneous apoptosis by a mean percentage of 53% (range, 20% to 129%) (P < .05) after 2 days in culture. On the third day, the mean percentage increase was 37% (range, 18% to 50%). In all cases, IL-4 protected B-CLL cells against IL-5-induced apoptosis by a mean percentage of 47% (range, 18% to 81%) (P < .001). This protection was specific to IL-4 and it was reduced with anti-IL-4 antibody. In addition, expression of bcl-2 protein in untreated cultures was not significantly different from that of the IL-5-treated cells; mean equivalent of soluble fluorochrome (MESF) was 5.2 (range, 3.0 to 6.8) and 4.9 (range, 3.0 to 6.3), respectively (P > .2). In freshly isolated B-CLL cells, the MESF was 4.5 (range, 2.4 to 6.6). These results show that IL-5 induced apoptosis in B-CLL cells by a pathway that is independent of bcl-2 expression. IL-4 partially protects against this effect.


Blood ◽  
2016 ◽  
Vol 127 (5) ◽  
pp. 582-595 ◽  
Author(s):  
Marwan Kwok ◽  
Nicholas Davies ◽  
Angelo Agathanggelou ◽  
Edward Smith ◽  
Ceri Oldreive ◽  
...  

Key PointsATR inhibition is synthetically lethal to TP53- or ATM-defective CLL cells. ATR targeting induces selective cytotoxicity and chemosensitization in TP53- or ATM-defective CLL cells in vitro and in vivo.


Blood ◽  
1997 ◽  
Vol 89 (9) ◽  
pp. 3378-3384 ◽  
Author(s):  
Beatriz Bellosillo ◽  
Mireia Dalmau ◽  
Dolors Colomer ◽  
Joan Gil

Abstract B-chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of long-lived B lymphocytes that express high levels of Bcl-2. We examined the involvement of CED-3/ICE-like proteases in the apoptosis of B-CLL cells. One of the substrates of these proteases is poly(ADP [adenosine 5′-diphosphate]-ribose) polymerase (PARP). The effect of different factors that induce the apoptosis of B-CLL cells on the proteolytic cleavage of PARP has been studied. Treatment of B-CLL cells with different concentrations of dexamethasone (1 to 1,000 μmol/L) induced in a dose-dependent manner the cleavage of PARP. Dexamethasone induced PARP cleavage after 12 hours of incubation, which was almost complete at 48 hours. PARP cleavage during apoptosis of B-CLL cells was studied in cells from eight patients and a correlation was found between cell viability and the degree of PARP cleavage. Incubation in vitro of B-CLL cells with fludarabine for 48 hours induced PARP cleavage in all the cases studied. Protein kinase C (PKC) activation with 100 nmol/L TPA (12-O-tetradecanoylphorbol 13-acetate) or incubation with interleukin-4 (10 ng/mL) prevented either dexamethasone- or fludarabine-induced proteolysis of PARP. Incubation of B-CLL cells with the CED-3/ICE–like protease inhibitor Z-VAD.fmk inhibited spontaneous and dexamethasone-induced PARP cleavage and DNA fragmentation in a dose-dependent manner. Furthermore, Z-VAD.fmk prevented the cytotoxic effect of dexamethasone. These results indicate that CED-3/ICE–like proteases play an important role in the apoptosis of B-CLL cells.


1994 ◽  
Vol 13 (1-2) ◽  
pp. 95-97 ◽  
Author(s):  
P. L. Zinzani ◽  
M. Buzzi ◽  
P. Farabegoli ◽  
P. Tosi ◽  
A. Fortuna ◽  
...  

2014 ◽  
Vol 38 (3) ◽  
pp. 411-417 ◽  
Author(s):  
Robert L. Dilley ◽  
Weijie Poh ◽  
Douglas E. Gladstone ◽  
James G. Herman ◽  
Margaret M. Showel ◽  
...  

2016 ◽  
Vol 44 (1) ◽  
pp. 38-49.e1 ◽  
Author(s):  
Sandra Eketorp Sylvan ◽  
Henriette Skribek ◽  
Stefan Norin ◽  
Orsolya Muhari ◽  
Anders Österborg ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (20) ◽  
pp. 3101-3109 ◽  
Author(s):  
Sergey Krysov ◽  
Andrew J. Steele ◽  
Vania Coelho ◽  
Adam Linley ◽  
Marina Sanchez Hidalgo ◽  
...  

Key Points Stimulation of the B-cell receptor of chronic lymphocytic leukemia cells results in activation of an unfolded protein response. Unfolded protein response activation following surface immunoglobulin M stimulation in vitro is dependent on the activity of BTK and SYK.


1992 ◽  
Vol 40 (4) ◽  
pp. 264-269 ◽  
Author(s):  
Ayad Ai-Katib ◽  
Chang Yi Wang ◽  
Susan McKenzie ◽  
Bayard D. Clarkson ◽  
Benjamin Koziner

Sign in / Sign up

Export Citation Format

Share Document